Published in Virchows Arch on January 14, 2004
Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch (2004) 3.04
Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med (2006) 2.08
Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol (2008) 1.14
Pancreatic malignant fibrous histiocytoma, inflammatory myofibroblastic tumor, and inflammatory pseudotumor related to autoimmune pancreatitis: characterization and differential diagnosis. Virchows Arch (2006) 0.97
Autoimmune pancreatitis: histo- and immunopathological features. J Gastroenterol (2007) 0.96
Recurrence of inflammatory pseudotumor in the distal bile duct: lessons learned from a single case and reported cases. World J Gastroenterol (2006) 0.89
Clinical analysis of 36 cases of autoimmune pancreatitis in China. PLoS One (2012) 0.83
Epstein-Barr virus-associated inflammatory pseudotumor presenting as a colonic mass. Hum Pathol (2015) 0.81
Inflammatory Myofibroblastic Tumor of the Pancreatic Head: An Unusual Cause of Recurrent Acute Pancreatitis - Case Presentation of a Palliative Approach after Failed Resection and Review of the Literature. Case Rep Gastroenterol (2010) 0.78
IVIM DW-MRI of autoimmune pancreatitis: therapy monitoring and differentiation from pancreatic cancer. Eur Radiol (2015) 0.78
Unusual case of pancreatic inflammatory myofibroblastic tumor associated with spontaneous splenic rupture. World J Emerg Surg (2010) 0.77
High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med (2001) 12.49
Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol (1995) 11.26
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res (1999) 3.46
Intestinal inflammatory pseudotumour with regional lymph node involvement: identification of a new bacterium as the aetiological agent. J Pathol (2000) 3.20
Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol (1990) 3.01
Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Semin Diagn Pathol (1998) 2.98
Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol (1994) 2.86
Postinflammatory tumors of the lung; report of four cases simulating xanthoma, fibroma, or plasma cell tumor. J Thorac Surg (1954) 2.51
Autoimmune pancreatitis: pathological, clinical, and immunological features. Pancreas (2003) 2.26
Frequent presence of the Epstein-Barr virus in inflammatory pseudotumor. Hum Pathol (1995) 2.22
Inflammatory myofibroblastic tumour (inflammatory pseudotumour) of the breast. Clinicopathological and genetic analysis of a case with evidence for clonality. J Pathol (2002) 1.87
The enigmatic inflammatory pseudotumours: the current state of our understanding, or misunderstanding. J Pathol (2000) 1.79
CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int (2002) 1.77
Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-beta 1 and myofibroblast accumulation. Am J Pathol (1997) 1.50
Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. J Gastrointest Surg (2003) 1.49
Progression of inflammatory myofibroblastic tumor (inflammatory pseudotumor) of soft tissue into sarcoma after several recurrences. Hum Pathol (1996) 1.45
Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int (2000) 1.41
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg (1999) 1.34
Inflammatory pseudotumor of lymph node and spleen: an entity biologically distinct from inflammatory myofibroblastic tumor. Hum Pathol (2001) 1.27
Presence of human herpesvirus-8 DNA sequences and overexpression of human IL-6 and cyclin D1 in inflammatory myofibroblastic tumor (inflammatory pseudotumor). Lab Invest (2000) 1.25
Myofibroblastic tumours: neoplasias with divergent behaviour. Ultrastructural and flow cytometric analysis. Pathol Res Pract (1999) 1.22
Rapid, nonradioactive detection of clonal T-cell receptor gene rearrangements in lymphoid neoplasms. Proc Natl Acad Sci U S A (1990) 1.16
Connective tissue growth factor in human liver cirrhosis. Liver (2000) 1.12
Inflammatory myofibroblastic tumor of the pancreaticobiliary region: morphologic and immunocytochemical study of three cases. Am J Surg Pathol (1998) 1.04
Inflammatory pseudotumour (inflammatory myofibroblastic tumour) of the pancreas: a report of six cases associated with obliterative phlebitis. Histopathology (2001) 0.97
Mast cell distribution and activation in chronic pancreatitis. Hum Pathol (2001) 0.96
Plasma cell granuloma of the pancreas. Arch Pathol Lab Med (1984) 0.93
Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol (2002) 0.88
Idiopathic fibrosclerotic disorders and other inflammatory pseudotumors. Semin Diagn Pathol (1998) 0.87
Endothelial cells at inflammatory sites as target for therapeutic intervention. Endothelium (2002) 0.87
Inflammatory pseudotumor of the pancreas. Int J Pancreatol (1995) 0.83
Vascular invasion by hepatic inflammatory pseudotumor. A clinicopathologic study. Cancer (1993) 0.83
[Inflammatory myofibroblastic tumor of the pancreas with regional lymph node involvement]. Pathologe (2002) 0.79
Rapidly progressive sclerosing cholangitis following surgical treatment of pancreatic pseudotumor. J Clin Gastroenterol (1995) 0.79
Connective tissue growth factor expression in pediatric myofibroblastic tumors. Pediatr Dev Pathol (2001) 0.78
Systemic idiopathic fibrosis with T-cell receptor gene rearrangement. Arch Pathol Lab Med (1991) 0.75
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg (2012) 7.26
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). Ann Surg (2013) 5.12
Colorectal cancer. Lancet (2005) 4.90
Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med (2010) 4.13
Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet (2011) 3.54
Recalling superior mesenteric artery syndrome. Dig Surg (2007) 3.52
IAP Guidelines for the Surgical Management of Acute Pancreatitis. Pancreatology (2002) 3.48
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg (2003) 3.12
Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg (2011) 3.10
Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg (2011) 2.92
Most pancreatic cancer resections are R1 resections. Ann Surg Oncol (2008) 2.79
Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology (2008) 2.76
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol (2012) 2.59
Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg (2007) 2.51
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery (2009) 2.29
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27
Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg (2008) 2.22
Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology (2007) 2.15
Toward the blood-borne miRNome of human diseases. Nat Methods (2011) 2.14
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology (2010) 2.10
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
Elective midline laparotomy closure: the INLINE systematic review and meta-analysis. Ann Surg (2010) 2.06
The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol (2008) 2.05
Interrupted or continuous slowly absorbable sutures for closure of primary elective midline abdominal incisions: a multicenter randomized trial (INSECT: ISRCTN24023541). Ann Surg (2009) 2.03
Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg (2011) 2.02
Surgical treatment of patients with wandering spleen: report of six cases with a review of the literature. Surg Today (2007) 2.02
Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol (2011) 2.02
Liver stiffness is directly influenced by central venous pressure. J Hepatol (2009) 2.00
Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.98
Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther (2008) 1.95
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg (2008) 1.93
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol (2012) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review. Am J Gastroenterol (2009) 1.88
The "artery first" approach for resection of pancreatic head cancer. J Am Coll Surg (2009) 1.86
Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg (2007) 1.85
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
TG13 flowchart for the management of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci (2013) 1.82
Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial. Ann Surg (2011) 1.81
Insertion of totally implantable venous access devices: an expertise-based, randomized, controlled trial (NCT00600444). Ann Surg (2011) 1.77
CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol (2012) 1.76
Care after colonic operation--is it evidence-based? Results from a multinational survey in Europe and the United States. J Am Coll Surg (2005) 1.76
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A (2009) 1.75
European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis (2013) 1.75
Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res (2005) 1.74
Combined laparoscopic-endoscopic resections of colorectal polyps: 10-year experience and follow-up. Surg Endosc (2009) 1.74
Pancreatic cancer microenvironment. Int J Cancer (2007) 1.73
Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol (2011) 1.72
Impaired autolysosome formation correlates with Lamp-2 depletion: role of apoptosis, autophagy, and necrosis in pancreatitis. Gastroenterology (2009) 1.72
Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol (2009) 1.70
Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol (2013) 1.69
Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. Arch Surg (2007) 1.69
Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. Gastroenterology (2008) 1.68
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene (2005) 1.67
Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67
TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci (2013) 1.66
Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas (2011) 1.64
Respiratory disease caused by a species B2 adenovirus in a military camp in Turkey. J Med Virol (2005) 1.64
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology (2013) 1.62
Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg (2015) 1.62
Invasion and metastasis in pancreatic cancer. Mol Cancer (2003) 1.61
Improvement of surgical results for pancreatic cancer. Lancet Oncol (2013) 1.60
Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg (2007) 1.60
Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol (2011) 1.59
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Renal cancer cell metastasis into the pancreas: a single-center experience and overview of the literature. Pancreas (2005) 1.58
Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.58
Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int (2011) 1.57
Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? Ann Surg (2011) 1.56